Migalastat · Galafold
Small molecule
Evidence outlook
Approved: Fabry Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- Treatment of Fabry disease in patients with GLA mutations categorized as amenable to treatment with migalastat
- GALAFOLD (migalastat capsules) is indicated for: • long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease [deficiency of α-galactosidase (α-Gal A)] and who have an α-Gal A mutation determined to be amenable by an in vitro assay (see 10.1 Mechanism of Action - Table 5).
- Galafold is indicated for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation (see the tables in section 5.1).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04020055 NCT04020055 · Fabry Disease Registry: NCT04020055 | 3 | Maximum observed concentration (Cmax) (Baseline through Month 12); Time to maximum concentration (tmax) (Baseline through Month 12); Apparent terminal elimination half-life (t½) (Baseline through Month 12); Concentration at the end of a dosing interval at steady state (Ctrough) (Baseline through Month 12); Average plasma migalastat concentration over the dosing interval (Cavg) (Baseline through Month 12); Area under the concentration-time curve at steady state during the dosing interval (AUC0-τ) (Baseline through Month 12); Area under the concentration-time curve from zero time (pre-dose) extrapolated to infinite time (AUC0-∞) (Baseline through Month 12); Apparent plasma clearance (CL/F) (Baseline through Month 12); Apparent terminal phase volume of distribution (Vz/F) (Baseline through Month 12); Dialysis clearance (CLD) (Baseline through Month 12); Volume of dialysate collected during the interval (VD) (Baseline through Month 12); Mean migalastat concentration in dialysate (CD) (Baseline through Month 12); Amount recovered in dialysate (AeD) (Baseline through Month 12); Fraction of the dose recovered in dialysate (FeD) (Baseline through Month 12); Mean migalastat plasma concentration during the dialysis interval (P) (Baseline through Month 12); Mean inlet area under the curve (AUCinlet) (Baseline through Month 12); Mean outlet area under the curve (AUCoutlet) (Baseline through Month 12); Extraction ratio (ED) (Baseline through Month 12); Dialyzer blood flow (QD) (Baseline through Month 12); Cumulative amount excreted over all collection intervals (Ae0-τ) (Baseline through Month 12); Fraction of the dose recovered after the last measurable time point postdose (Fe0-τ) (Baseline through Month 12); Renal clearance (CLr) (Baseline through Month 12) 2026-12-31 | In progress: results expected 31 Dec 2026 | not yet graded | link ↗ |
View 5 more trials
NCT00925301 NCT00925301 · Fabry Disease Participants were randomized and double-blinded to migalastat or placebo, with 34 and 33 participants assigned respectively. The primary endpoint was a kidney biopsy measure of GL-3 inclusions, a surrogate pathology measure rather than a direct clinical outcome; 13 of 32 migalastat-treated participants versus 9 of 32 placebo-treated participants achieved the target reduction, but the comparison was not statistically significant (p=0.2996). Registry: NCT00925301 | 3 | Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6) 2012-06-12 | Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants | Partial signal | link ↗ |
NCT01218659 NCT01218659 · Fabry Disease Registry: NCT01218659 | 3 | Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate; Annualized Rate Of Change From Baseline To Month 18 In eGFR 2014-05-27 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
NCT04049760 NCT04049760 · Fabry Disease This was a single-arm, unblinded continuation study of 16 participants from the completed AT1001-020 trial, with no placebo or active comparator. Its primary safety endpoint was descriptive rather than a formal between-group comparison, so the reported adverse-event findings provide limited controlled evidence despite the explicitly stated continuation from the prior trial. Registry: NCT04049760 | 3 | Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug (Entire study) 2024-11-29 | Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and AEs (Adverse Events) Leading to Discontinuation of Study Drug (Entire study): Migalastat HCl 150 mg — Number of subjects with TEAEs: 13 Participants; Number of subjects with SAE: 1 Participants; Number of subjects with AE leading to discontinuation: 0 Participants | Weak signal | link ↗ |
NCT03500094 NCT03500094 · Fabry Disease This was a small, open-label, single-arm study of 22 participants, with no placebo or active comparator and no randomization or blinding. Its primary outcomes were treatment-related adverse events and pharmacokinetic measures rather than a controlled clinical efficacy endpoint, so the results cannot establish comparative benefit. Registry: NCT03500094 | 3 | Number Of Participants Who Experienced Treatment-related Treatment-emergent Adverse Events (TEAEs) (Day 1 (after dosing) through Month 12 and follow-up (30 days after last dose)); Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve Over The Dosing Interval (AUCtau) Of Migalastat (0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12); PK: Maximum Observed Plasma Concentration (Cmax) Of Migalastat (0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12) 2021-02-02 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
NCT00304512 NCT00304512 · Fabry Disease This was a very small, unblinded study with only 2 to 4 patients per dose group and no placebo or comparator arm, so while no participant experienced a severe side effect, the study is too small and uncontrolled to demonstrate the drug's efficacy. Registry: NCT00304512 | 2 | Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) (Day 1 (after dosing) through Week 48) 2008-05-09 | This open-label, uncontrolled study ran 12 weeks with extension to 48 weeks in nine females with Fabry disease. Migalastat HCl was generally well tolerated, and the greatest declines in urine GL-3 were observed in the three patients with amenable GLA mutations treated with 150 or 250 mg migalastat HCl every other day. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
Other Alpha-galactosidase A (GLA / α-Gal A) drugs
Agalsidase beta, pegunigalsidase alfa, isaralgagene civaparvovec. Compare all 4 Alpha-galactosidase A (GLA / α-Gal A) drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Fabry Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Migalastat (Galafold): this drug | Approved | Small molecule | Alpha-galactosidase A (GLA / α-Gal A) | Partial signal | NCT00925301: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants missed | |
| Agalsidase Beta (Fabrazyme) | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | Weak signal | NCT00701415: Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks). NCT00196716: Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase. | |
| Pegunigalsidase Alfa | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | Weak signal | NCT02795676: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) | |
| Isaralgagene Civaparvovec | Phase 1/2 | Gene therapy / editing | Alpha-galactosidase A (GLA / α-Gal A) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Galafold (Migalastat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.